Drugs / UB-612
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05167253 | Feb → Apr 2022 | COVID-19 | United Biomedical Inc., Asia | Withdrawn | No outcome recorded |
| Phase 1 | NCT04967742 | Aug 2021 | COVID-19 | United Biomedical Inc., Asia | Completed | No outcome recorded |
| Phase 1 | NCT04545749 | Sep 2020 → Jan 2021 | COVID-19 | United Biomedical Inc., Asia | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04773067 | Jan 2021 → Mar 2022 | COVID-19 | United Biomedical Inc., Asia | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04683224 | Feb 2021 → Mar 2023 | COVID-19 | Vaxxinity, Inc. | Withdrawn | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT05293665 | Mar → Nov 2022 | — | Vaxxinity, Inc. | Unknown | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UB-612 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04545749 ↗ |
| Modality | Vaccine | “a multitope subunit vaccine” PMID 35316221 ↗ May 2022 |
| Route | Intramuscular | “as an intramuscular (IM) injection” NCT04683224 ↗ |